🩸 Happy #BloodCancerAwarenessMonth from the BCT editorial board! As blood cancer awareness continues, explore expert insights and clinical updates here. ➡️ buff.ly/mcFuxs2 Mehdi Hamadani, MD Krina Patel Tycel Phillips Dr. Uma Borate: Associate Professor Rahul Banerjee, MD, FACP Hira Mian

Thank you everyone for making #IMS25 a huge success. Thank you Myeloma Society for hosting in Toronto. Wonderful science, wonderful presentations and wonderful colleagues from across the world Looking forward to #IMS26 Gordon Cook

The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma Leukemia Journal nature.com/articles/s4137…

We are one mighty city! A small city in Canada but the top for fundraising Myeloma Hamilton kudos!!

ahhh so terrific...we'll have to ensure Gordon Cook has you officially incorporated into the #IMS26! Myeloma Society

ASH Oral Abstracts out! #ash25

IFM2017-03: Dara-R (with dex for cycles 1-2 only) vs Rd for frail older adults. No surprise here: Dara-R > Rd, but there's more to it! 🕐The median age in this trial was 81! 👵All patients had IFM frailty score>=2 ! ➡️Nearly every subgroup statistically benefitted from

Cevostamab combined with pomalidomide and dexamethasone showed encouraging responses and safety for relapsed or refractory multiple #myeloma. Read more from a dose-expansion arm of the CAMMA 1 study presented by Hira Mian, of McMaster University, at #IMS25. 📖 buff.ly/aarWyyA

MRD negative in myeloma requires a complete response (CR), including no detectable monoclonal protein. That’s the IMWG criteria. Criteria are not meant to be perfect. Experts will always disagree on some aspect. If everyone uses their own criteria we cannot interpret studies.

#Myeloma Paper of the Day: SEMA4A expression is hi where BCMA density is low; its deletion limits myeloma cell growth, migration, tissue infiltration, & osteoclast formation; CAR T cells show superior efficacy vs. BCMA CAR T in pre-clinical models: pubmed.ncbi.nlm.nih.gov/41072416/. #mmsm

Thansk Marc S. Raab for this nice editorial highlighting our recent paper on Blood Cancer Discovery nizar jacques bahlis ⁦Holly Lee ⁩ #PaolaNeri #MariosPapdimitious Ben Diamond, MD #mmsm Memorial Sloan Kettering Cancer Center 👇👇👇

Sigh

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care jnj.com/media-center/p…

Toronto's University Health Network raised $30 million for Canada Leads to attract the best scientists. 25 are recruited and 75 more will be finalized. As the U.S. implodes - Canada steps up. Key reporting by Avis Favaro on Brad Wouters 🇨🇦 University Health Network UHN Foundation Dr. Kevin Smith

Another big hit for #CTCs in #mmsm, this time by the Rotterdam group (Erasmus MC Intl). Beautiful and very important study! Congrants, Luca Bertamini and the rest of the team! ashpublications.org/blood/article/…

🚨Calling all myeloma clinicians! What diagnostics are you using to help with treatment decisions at diagnosis and relapse? Karyotype? FISH? NGS panels? We want to know! Fill out this quick (dare I say fun!) survey here: bit.ly/Guide-MM

We're in Charleston, SC, for #iwHRMM25! Kicking off an exciting meeting focusing on high-risk #myeloma is Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 of Memorial Sloan Kettering Cancer Center. 🩸 #MMSM #MultipleMyeloma #HemOnc #ImmunoOnc

At #iwHRMM25, Jonathan Licht (Jonathan Licht, MD) of UF Health Cancer Center is speaking on enhancing glucocorticoid activity in #MultipleMyeloma. #MMSM #Myeloma #HemOnc

Next up at #iwHRMM25, Doris Hansen (Moffitt Cancer Center) will highlight the optimization of CAR T-cell therapy for high-risk #MultipleMyeloma.💉🩸 #MMSM #Myeloma #HemOnc #ImmunoOnc #CARTCell

Amazing job friends!